Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 13.

Jenni, D; Karpova, M B; Mühleisen, B; Mangana, J; Dreier, J; Hafner, J; Dummer, R (2016). A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis. ESMO Open, 1:e000003.

Fujii, K; Karpova, M B; Asagoe, K; Georgiev, O; Dummer, R; Urosevic-Maiwald, M (2015). Versican upregulation in Sézary cells alters growth, motility and resistance to chemotherapy. Leukemia, 29(10):2024-2032.

Puga Yung, G; Borsig, L; Millard, A L; Karpova, M B; Zhou, D; Seebach, J D (2012). Complete absence of the αGal xenoantigen and isoglobotrihexosylceramide in α1,3galactosyltransferase knock-out pigs. Xenotransplantation, 19(3):196-206.

Dummer, R; Goldinger, S M; Cozzio, A; French, L E; Karpova, M B (2012). Cutaneous lymphomas: Molecular pathways leading to new drugs. Journal of Investigative Dermatology, 132(3):517-525.

Mangana, J; Lévesque, M P; Karpova, M B; Dummer, R (2012). Sorafenib in melanoma. Expert Opinion on Investigational Drugs, 21(4):557-568.

Barysch, M J; Rümmelein, B; Kolm, I; Karpova, M B; Schönewolf, N; Bogdan Allemann, I; Dummer, R (2012). Split-face study of melasma patients treated with non-ablative fractionated photothermolysis (1540 nm). Journal of the European Academy of Dermatology and Venereology, 26(4):423-430.

Karpova, M B; Barysch, M J; Zipser, M C; Schönewolf, N; French, L E; Dummer, R (2011). Changing pathology with changing drugs: skin cancer. Pathobiology, 78(2):61-75.

Karpova, M B; Fujii, K; Jenni, D; Dummer, R; Urosevic-Maiwald, M (2011). Evaluation of lymphangiogenic markers in Sézary syndrome. Leukemia and Lymphoma, 52(3):491-501.

Kiessling, M K; Oberholzer, P A; Mondal, C; Karpova, M B; Zipser, M C; Lin, W M; Girardi, M; MacConaill, L E; Kehoe, S M; Hatton, C; French, L E; Garraway, L A; Polier, G; Süss, D; Klemke, C D; Krammer, P H; Gülow, K; Dummer, R (2011). High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood, 117(8):2433-2440.

Sánchez-Schmidt, J M; Salgado, R; Servitje, O; Gallardo, F; Ortiz-Romero, P L; Karpova, M B; Zipser, M C; García-Muret, M P; Estrach, T; Rodríguez-Pinilla, S M; Climent, F; Suela, J; Ferreira, B I; Cigudosa, J C; Salido, M; Barranco, C; Serrano, S; Dummer, R; Solé, F; Pujol, R M; Espinet, B (2011). Primary cutaneous CD30+ anaplastic large-cell lymphomas show a heterogeneous genomic profile: an oligonucleotide arrayCGH approach. Journal of Investigative Dermatology, 131(1):269-271.

Jenni, D; Karpova, M B; Seifert, Burkhardt; Golling, P; Cozzio, A; Kempf, W; French, L E; Dummer, R (2011). Primary cutaneous lymphoma: Two-decade comparison in a population of 263 cases from a Swiss tertiary referral centre. British Journal of Dermatology, 164(5):1071-1077.

Salgado, R; Servitje, O; Gallardo, F; Vermeer, M H; Ortiz-Romero, P L; Karpova, M B; Zipser, M C; Muniesa, C; García-Muret, M P; Estrach, T; Salido, M; Sánchez-Schmidt, J; Herrera, M; Romagosa, V; Suela, J; Ferreira, B I; Cigudosa, J C; Barranco, C; Serrano, S; Dummer, R; Tensen, C P; Solé, F; Pujol, R M; Espinet, B (2009). Oligonucleotide array-cgh identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides. Journal of Investigative Dermatology, 130(4):1126-1135.

Emery, C M; Vijayendran, K G; Zipser, M C; Sawyer, A M; Niu, L; Kim, J J; Hatton, C; Chopra, R; Oberholzer, P A; Karpova, M B; MacConaill, L E; Zhang, J; Gray, N S; Sellers, W R; Dummer, R; Garraway, L A (2009). MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 106(48):20411-20416.

This list was generated on Sat Oct 21 02:43:09 2017 CEST.